From GlobeNewswire: 2025-06-11 07:30:00

Ocugen, Inc. will present at the 2025 BIO International Convention in Boston from June 16-19, 2025. The company’s modifier gene therapy platform is targeting major blindness diseases with a one-time therapy for life. Ocugen recently secured a binding term sheet with a Korean pharmaceutical leader for exclusive rights to OCU400. The company’s modifier gene therapy platform has achieved FDA alignment for pivotal trials and Rare Pediatric Disease Designation for OCU410ST. Ocugen’s CEO, Dr. Shankar Musunuri, will participate in various speaking opportunities at BIO and the Longwood Healthcare Leaders MIT CEO Conference. Visit Booth #1875 for more information.



Read more at GlobeNewswire: Ocugen To Present at BIO International Convention 2025